{"nctId":"NCT01062568","briefTitle":"The Adrenal Contribution to Androgen Production in Girls During Puberty","startDateStruct":{"date":"2010-02"},"conditions":["Development"],"count":50,"armGroups":[{"label":"Obese group","type":"EXPERIMENTAL","interventionNames":["Drug: Adrenocorticotropin","Drug: Dexamethasone"]},{"label":"Nonobese group","type":"EXPERIMENTAL","interventionNames":["Drug: Adrenocorticotropin","Drug: Dexamethasone"]}],"interventions":[{"name":"Adrenocorticotropin","otherNames":["Cosyntropin","ACTH"]},{"name":"Dexamethasone","otherNames":["dex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Normal CBC (Hemoglobin must be at least 11mg/dl)\n* Normal renal and liver function tests (AST\\& ALT 10-45 IU/L; Albumin 3.3-5 g/dL; Alk phos 30-130 IU/L;\n* direct bili \\<0.2 mg/dL;\n* total bili \\<1.2 mg/dL; total protein 6.0-8.0 g/dL) Normal vital signs including normal blood pressure (pulse 60-100/min, respirations 12-20/min, BP 80/60-130/80)\n\nExclusion Criteria:\n\n* Pregnancy\n* On oral contraceptives\n* On insulin lowering drugs\n* On anti-androgens (i.e., spironolactone, flutamide, finasteride, etc)\n* On medications that will influence androgen metabolism or clearance\n* On medications that will inhibit the cytochrome P450 enzyme system (cimetidine, ketoconazole, etc)\n* Subjects with morning cortisol\\<5 ug/dL will be excluded and asked to see their primary care physician.\n* Subjects with 17-OHP\\>250 ng/dL) will be excluded and asked to see their primary care physician.\n* Subject with a history of Cushing syndrome or adrenal insufficiency will be excluded","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"7 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"17-hydroxyprogesterone Response to ACTH","description":"17-hyrooxyprogesterone levels before and after ACTH","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.5"},{"groupId":"OG001","value":"3.7","spread":"0.8"},{"groupId":"OG002","value":"3.1","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.4"},{"groupId":"OG001","value":"3.1","spread":"0.7"},{"groupId":"OG002","value":"3.0","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Free Testosterone Response to ACTH","description":"Free Testosteorne levels before and after ACTH","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"0.3"},{"groupId":"OG001","value":"7","spread":"1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.4"},{"groupId":"OG001","value":"32","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Androstenedione Response to ACTH","description":"Androstenedione levels before and after ACTH","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.1"},{"groupId":"OG001","value":"1.6","spread":"0.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.2"},{"groupId":"OG001","value":"3.1","spread":"0.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}}